{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T07:13:34Z","timestamp":1791443614410,"version":"4.3.3"},"reference-count":60,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T00:00:00Z","timestamp":1707868800000},"content-version":"unspecified","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Breast Cancer Now","award":["CTR-Q4-Y1-5, CTR-Q5-Y1"],"award-info":[{"award-number":["CTR-Q4-Y1-5, CTR-Q5-Y1"]}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["PhD studentship"],"award-info":[{"award-number":["PhD studentship"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2024,1,25]]},"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Targeting of solid cancers with chimeric antigen receptor (CAR)-T cells is limited by the lack of suitable tumor-specific antigens and the immunosuppressive, desmoplastic tumor microenvironment that impedes CAR-T cell infiltration, activity and persistence. We hypothesized that targeting the endosialin (CD248) receptor, strongly expressed by tumor-associated pericytes and perivascular cancer-associated fibroblasts, would circumvent these challenges and offer an exciting antigen for CAR-T cell therapy due to the close proximity of target cells to the tumor vasculature, the limited endosialin expression in normal tissues and the lack of phenotype observed in endosialin knockout mice.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We generated endosialin-directed E3K CAR-T cells from three immunocompetent mouse strains, BALB\/c, FVB\/N and C57BL\/6. E3K CAR-T cell composition (CD4<jats:sup>+<\/jats:sup>\/CD8<jats:sup>+<\/jats:sup> ratio), activity in vitro against endosialin<jats:sup>+<\/jats:sup> and endosialin<jats:sup>\u2013<\/jats:sup> cells, and expansion and activity in vivo in syngeneic tumor models as well as in tumor-naive healthy and wounded mice and tumor-bearing endosialin knockout mice was assessed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>E3K CAR-T cells were active in vitro against both mouse and human endosialin<jats:sup>+<\/jats:sup>, but not endosialin<jats:sup>\u2013<\/jats:sup>, cells. Adoptively transferred E3K CAR-T cells exhibited no activity in endosialin knockout mice, tumor-naive endosialin wildtype mice or in wound healing models, demonstrating an absence of off-target and on-target\/off-tumor activity. By contrast, adoptive transfer of E3K CAR-T cells into BALB\/c, FVB\/N or C57BL\/6 mice bearing syngeneic breast or lung cancer lines depleted target cells in the tumor stroma resulting in increased tumor necrosis, reduced tumor growth and a substantial impairment in metastatic outgrowth.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Together these data highlight endosialin as a viable antigen for CAR-T cell therapy and that targeting stromal cells closely associated with the tumor vasculature avoids CAR-T cells having to navigate the harsh immunosuppressive tumor microenvironment. Further, the ability of E3K CAR-T cells to recognize and target both mouse and human endosialin<jats:sup>+<\/jats:sup> cells makes a humanized and optimized E3K CAR a promising candidate for clinical development applicable to a broad range of solid tumor types.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2023-008608","type":"journal-article","created":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T20:15:20Z","timestamp":1709064920000},"page":"e008608","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":36,"title":["Targeting the activated microenvironment with endosialin (CD248)-directed CAR-T cells ablates perivascular cells to impair tumor growth and metastasis"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3866-0237","authenticated-orcid":false,"given":"Sarah L","family":"Ash","sequence":"first","affiliation":[{"name":"The Institute of Cancer Research, London, UK"},{"name":"Department of Oncology, University of Lausanne, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1740-5616","authenticated-orcid":false,"given":"Rebecca","family":"Orha","sequence":"additional","affiliation":[{"name":"The Institute of Cancer Research, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0195-3033","authenticated-orcid":false,"given":"Holly","family":"Mole","sequence":"additional","affiliation":[{"name":"University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1361-690X","authenticated-orcid":false,"given":"Meg","family":"Dinesh-Kumar","sequence":"additional","affiliation":[{"name":"The Institute of Cancer Research, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P","family":"Lee","sequence":"additional","affiliation":[{"name":"University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6649-6198","authenticated-orcid":false,"given":"Frances K","family":"Turrell","sequence":"additional","affiliation":[{"name":"The Institute of Cancer Research, London, UK"},{"name":"Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9222-3345","authenticated-orcid":false,"given":"Clare M","family":"Isacke","sequence":"additional","affiliation":[{"name":"The Institute of Cancer Research, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,2,27]]},"reference":[{"key":"2025100300200680000_12.2.e008608.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2210859"},{"key":"2025100300200680000_12.2.e008608.2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","article-title":"CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn","volume":"21","author":"Albelda","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"2025100300200680000_12.2.e008608.3","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00281-022-00962-4","article-title":"Beyond direct killing-novel cellular immunotherapeutic strategies to reshape the tumor microenvironment","volume":"45","author":"Huynh","year":"2023","journal-title":"Semin Immunopathol"},{"key":"2025100300200680000_12.2.e008608.4","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-40850-5","article-title":"Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors","volume":"14","author":"Xiao","year":"2023","journal-title":"Nat Commun"},{"key":"2025100300200680000_12.2.e008608.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.10.474"},{"key":"2025100300200680000_12.2.e008608.6","doi-asserted-by":"publisher","DOI":"10.1126\/science.289.5482.1197"},{"key":"2025100300200680000_12.2.e008608.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.mvr.2008.07.008"},{"key":"2025100300200680000_12.2.e008608.8","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2008.070623"},{"key":"2025100300200680000_12.2.e008608.9","doi-asserted-by":"publisher","DOI":"10.1111\/j.0303-6987.2006.00446.x"},{"key":"2025100300200680000_12.2.e008608.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2005.03.071"},{"key":"2025100300200680000_12.2.e008608.11","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3801006"},{"key":"2025100300200680000_12.2.e008608.12","doi-asserted-by":"publisher","DOI":"10.1111\/febs.14985"},{"key":"2025100300200680000_12.2.e008608.13","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0511306103"},{"key":"2025100300200680000_12.2.e008608.14","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-0932"},{"key":"2025100300200680000_12.2.e008608.15","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.12.6166"},{"key":"2025100300200680000_12.2.e008608.16","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4049\/jimmunol.182.Supp.129.5","article-title":"Differences in antibody and immune responses between Balb\/c and C57Bl\/6 mice infected with Trypanosoma cruzi (129.5)","volume":"182","author":"Guyach","year":"2009","journal-title":"J Immunol"},{"key":"2025100300200680000_12.2.e008608.17","doi-asserted-by":"publisher","DOI":"10.1172\/JCI43490"},{"key":"2025100300200680000_12.2.e008608.18","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1302148"},{"key":"2025100300200680000_12.2.e008608.19","doi-asserted-by":"crossref","DOI":"10.1186\/s13058-018-1093-9","article-title":"Using an in-vivo syngeneic spontaneous metastasis model identifies ID2 as a promoter of breast cancer colonisation in the brain","volume":"21","author":"Kijewska","year":"2019","journal-title":"Breast Cancer Res"},{"key":"2025100300200680000_12.2.e008608.20","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2402"},{"key":"2025100300200680000_12.2.e008608.21","doi-asserted-by":"publisher","DOI":"10.1089\/104303403322167993"},{"key":"2025100300200680000_12.2.e008608.22","doi-asserted-by":"publisher","DOI":"10.1006\/mthe.2000.0068"},{"key":"2025100300200680000_12.2.e008608.23","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.138808","article-title":"CAR T cells targeting tumor endothelial marker CLEC14A inhibit tumor growth","volume":"5","author":"Zhuang","year":"2020","journal-title":"JCI Insight"},{"key":"2025100300200680000_12.2.e008608.24","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-2408"},{"key":"2025100300200680000_12.2.e008608.25","article-title":"The ARRIVE guidelines 2.0: updated guidelines for reporting animal research","volume":"4","author":"Percie du Sert","year":"2020","journal-title":"BMJ Open Sci"},{"key":"2025100300200680000_12.2.e008608.26","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/s43018-023-00525-y","article-title":"Age-associated microenvironmental changes highlight the role of PDGF-C in ER+ breast cancer metastatic relapse","volume":"4","author":"Turrell","year":"2023","journal-title":"Nat Cancer"},{"key":"2025100300200680000_12.2.e008608.27","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-3496"},{"key":"2025100300200680000_12.2.e008608.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.modgep.2006.07.006"},{"key":"2025100300200680000_12.2.e008608.29","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-008-9982-8"},{"key":"2025100300200680000_12.2.e008608.30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1078"},{"key":"2025100300200680000_12.2.e008608.31","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2013-5016"},{"key":"2025100300200680000_12.2.e008608.32","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-021-00885-z","article-title":"Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis","volume":"13","author":"Wu","year":"2021","journal-title":"Genome Med"},{"key":"2025100300200680000_12.2.e008608.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.08.003"},{"key":"2025100300200680000_12.2.e008608.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.03.016"},{"key":"2025100300200680000_12.2.e008608.35","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/s43018-022-00411-z","article-title":"Cancer-associated fibroblasts in the single-cell era","volume":"3","author":"Lavie","year":"2022","journal-title":"Nat Cancer"},{"key":"2025100300200680000_12.2.e008608.36","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0096-5"},{"key":"2025100300200680000_12.2.e008608.37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061338","article-title":"CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia","volume":"8","author":"Davila","year":"2013","journal-title":"PLoS One"},{"key":"2025100300200680000_12.2.e008608.38","doi-asserted-by":"crossref","first-page":"5344","DOI":"10.1182\/bloodadvances.2021005020","article-title":"Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma","volume":"5","author":"Kennedy","year":"2021","journal-title":"Blood Adv"},{"key":"2025100300200680000_12.2.e008608.39","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-2997"},{"key":"2025100300200680000_12.2.e008608.40","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.663201","article-title":"Reactions related to CAR-T cell therapy","volume":"12","author":"Miao","year":"2021","journal-title":"Front Immunol"},{"key":"2025100300200680000_12.2.e008608.41","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10305","article-title":"Tumour cell-derived Wnt7a recruits and activates fibroblasts to promote tumour aggressiveness","volume":"7","author":"Avgustinova","year":"2016","journal-title":"Nat Commun"},{"key":"2025100300200680000_12.2.e008608.42","doi-asserted-by":"publisher","DOI":"10.1038\/nature07623"},{"key":"2025100300200680000_12.2.e008608.43","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2021.100362","article-title":"Soluble trivalent engagers redirect cytolytic T cell activity toward tumor endothelial marker 1","volume":"2","author":"Fierle","year":"2021","journal-title":"Cell Rep Med"},{"key":"2025100300200680000_12.2.e008608.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2011.11.024"},{"key":"2025100300200680000_12.2.e008608.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2014.04.005"},{"key":"2025100300200680000_12.2.e008608.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2014.04.021"},{"key":"2025100300200680000_12.2.e008608.47","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-21-4141"},{"key":"2025100300200680000_12.2.e008608.48","doi-asserted-by":"publisher","DOI":"10.1097\/01.cji.0000436722.46675.4a"},{"key":"2025100300200680000_12.2.e008608.49","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15695"},{"key":"2025100300200680000_12.2.e008608.50","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/imr.13252","article-title":"Coengineering specificity, safety, and function into T cells for cancer immunotherapy","volume":"320","author":"Giordano Attianese","year":"2023","journal-title":"Immunol Rev"},{"key":"2025100300200680000_12.2.e008608.51","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133977","article-title":"TGF-\u03b2 inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors","volume":"5","author":"Tang","year":"2020","journal-title":"JCI Insight"},{"key":"2025100300200680000_12.2.e008608.52","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-021-01128-9","article-title":"IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin","volume":"14","author":"Pang","year":"2021","journal-title":"J Hematol Oncol"},{"key":"2025100300200680000_12.2.e008608.53","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0040"},{"key":"2025100300200680000_12.2.e008608.54","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1084"},{"key":"2025100300200680000_12.2.e008608.55","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-793141"},{"key":"2025100300200680000_12.2.e008608.56","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/j.cell.2022.03.041","article-title":"Enhanced safety and efficacy of protease-regulated CAR-T cell receptors","volume":"185","author":"Labanieh","year":"2022","journal-title":"Cell"},{"key":"2025100300200680000_12.2.e008608.57","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.ccell.2022.08.008","article-title":"High-performance multiplex drug-gated CAR circuits","volume":"40","author":"Li","year":"2022","journal-title":"Cancer Cell"},{"key":"2025100300200680000_12.2.e008608.58","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ejca.2017.10.035","article-title":"Tumour endothelial marker 1\/endosialin-mediated targeting of human sarcoma","volume":"90","author":"Guo","year":"2018","journal-title":"Eur J Cancer"},{"key":"2025100300200680000_12.2.e008608.59","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0499"},{"key":"2025100300200680000_12.2.e008608.60","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.214"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2023-008608","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T07:20:18Z","timestamp":1759476018000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2023-008608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":60,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2,27]]},"published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1136\/jitc-2023-008608"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2023-008608","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]}}}